Sugi Predict

Sugi Predict / Compounds / SCHEMBL65017

SCHEMBL65017

SCHEMBL65017

CC(C)(C)OC(=O)N1CCN(C2CCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.54
▸ EPHX1 P07099 1/20 0.51
▸ USP2 O75604 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ RECQL P46063 1/20 0.48
▸ OPRM1 P35372 1/20 0.47
▸ OPRD1 P41143 1/20 0.47
▸ OGFRL1 Q5TC84 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ PREP P48147 1/20 0.46
▸ EPHX2 P34913 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ GPR119 Q8TDV5 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971010 0.97 EPHX1 (0.55) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL600317 0.95 HPGD (0.54) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL4383127 0.95 EPHX1 (0.57) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL63877 0.93 USP2 (0.53) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL1507159 0.92 HPGD (0.54) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL3968036 0.92 OPRM1 (0.55) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL6135150 0.91 HPGD (0.56) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL3917887 0.90 HPGD (0.55) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL31583968 0.88 HPGD (0.47) HPGDEPHX1USP2SMN1; SMN2RECQL
SCHEMBL29001643 0.88 CHRM2 (0.51) HPGDEPHX1USP2SMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022268229-A1 PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE 和径医药科技（上海）有限公司 2022-12-29 — — WO disclosed
US-10301267-B2 Compounds ASTRAZENECA AB (SE) 2019-05-28 — — US disclosed
US-20170275264-A1 CARBAMATE/UREA DERIVATIVES NOVARTIS AG (CH) 2017-09-28 — — US disclosed
US-20170275264-A1 CARBAMATE/UREA DERIVATIVES NOVARTIS AG (CH) 2017-09-28 — — US disclosed
US-20170275264-A1 CARBAMATE/UREA DERIVATIVES NOVARTIS AG (CH) 2017-09-28 — — US disclosed
US-20170260143-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2017-09-14 — — US disclosed
EP-2875016-B1 CARBAMATE/UREA DERIVATIVES NOVARTIS AG (CH) 2017-08-23 — — EP disclosed
EP-2875016-B1 CARBAMATE/UREA DERIVATIVES NOVARTIS AG (CH) 2017-08-23 — — EP disclosed
US-9688640-B2 Methods of treating cancer with a pyrazole derivative ASTRAZENECA AB (SE) 2017-06-27 — — US disclosed
US-9624192-B2 Carbamate/urea derivatives NOVARTIS AG (CH) 2017-04-18 — — US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 — — US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 — — US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 — — US disclosed
US-20070054917-A1 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases GLAXO GROUP LIMITED (GB) 2007-03-08 — — US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 — — CN disclosed
EP-1615909-A1 PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES GLAXO GROUP LIMITED (GB) 2006-01-18 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed
WO-2004101546-A1 PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES GLAXO GROUP LIMITED (GB) 2004-11-25 — — WO disclosed
US-20040019039-A1 Substituted piperazines and diazepanes HIGH POINT PHARMACEUTICALS, LLC 2004-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054917-A1 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases GRIN2A, GRIK5, GRIN2C HPGD 1179/4885EPHX1 1504/4885USP2 2077/4885
US-20170275264-A1 CARBAMATE/UREA DERIVATIVES SLC14A1, CPS1, REN HPGD 2540/4885EPHX1 4245/4885USP2 187/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 HPGD 18/4885EPHX1 1559/4885USP2 3881/4885
US-10301267-B2 Compounds SLC10A1, CYP11B1, ABCB11 HPGD 612/4885EPHX1 1894/4885USP2 4725/4885
US-20040019039-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 HPGD 646/4885EPHX1 752/4885USP2 2350/4885
US-20170260143-A1 NOVEL COMPOUNDS SLC10A1, ABCB11, CYP11B1 HPGD 918/4885EPHX1 2000/4885USP2 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.